International Journal of Computational and Experimental Science and ENgineering (IJCESEN)

Vol. 11-No.4 (2025) pp. 7230-7243
http://www.ijcesen.com

ISSN: 2149-9144

Research Article

Management of Head and Neck Cancer a Multidisciplinary Collaboration Involving Oncology, Dentistry, Nursing, Pharmacy, Neurology, and Critical Care

Khalid Omar A Bin Haylan[1]*, Najeed Nizar Balilah[2], Shawqi Asad Almushrif[3], Kuthar Hassan Alzaher[4], Saeed Mohammed Dream[5], Alahmary Ahmad Dhafer A[6], Harun Baqer Alshaikh[7], Osamah Hassan Abouzaed[8], Fahad Hassan Alzahrani[9], Ibrahim Ateeq Alamri[10], Hassan Abdullah Alagoul[11]

[1] Nursing Specialist - General Directorate OF Prisons Health - Saudi Arabia
* **Corresponding Author Email:** khaledomar43219@gmail.com - **ORCID:** 0000-0002-0047-7850

[2] Neurosurgery specialist - King Faisal Hospital Makkah - Saudi Arabia
Email: nbalilah@moh.gov.sa - **ORCID:** 0000-0002-1147-7850

[3]Clinical Microbiology PhD, Clinical Pathology MMS, Clinical Laboratory Science Bachelor - Dammam Comprehensive Screening Centre - Saudi Arabia
Email: almushrif@hotmail.com- **ORCID:** 0000-0002-2247-7850

[4] Dentistry - Ministry of Health Qatif Central Hospital - Saudi Arabia
Email: dreamy_pink@hotmail.com- **ORCID:** 0000-0002-3347-7850

[5]General Practitioner Physician - Tendaha Alzalal PHC - Saudi Arabia
Email: ssaaeed3322@gmail.com- **ORCID:** 0000-0002-4447-7850

[6] ICU Resident, Ministry of Health - Saudi Arabia
Email: dr.ahmary@gmail.com - **ORCID:** 0000-0002-5547-7850

[7]Pharmacist - MOH - Prince Saud Bin Jalawi Hospital - Saudi Arabia
Email: haron-1990@hotmail.com- **ORCID:** 0000-0002-6647-7850

[8]Laboratory Specialist - Qaryat Alolaya Hospital - Saudi Arabia
Email: osamah.hassan.abouzaed@gmail.com - **ORCID:** 0000-0002-7747-7850

[9]Laboratory Technician - Central Blood Bank in Dammam - Saudi Arabia
Email: fahad.hassan.alzahrani@gmail.com- **ORCID:** 0000-0002-8847-7850

[10]Laboratory Specialist - Central Blood Bank in Dammam - Saudi Arabia
Email: ibrahim.ateeq.alamri@gmail.com- **ORCID:** 0000-0002-9947-7850

[11]Laboratory Technician - Central Blood Bank in Dammam - Saudi Arabia
Email: hassan.abdullah.alagoul@gmail.com- **ORCID:** 0000-0002-0047-7850

Article Info:

DOI: 10.22399/ijcesen.3998
Received : 01 January 2025
Accepted : 27 January 2025

Keywords

Head and Neck Cancer;
Multidisciplinary Team (MDT);
Oncology;
Surgical Management;
Reconstructive Surgery;
Medical Oncology

Abstract:

The management of head and neck cancer necessitates a comprehensive and multidisciplinary approach, integrating various specialties to provide the most effective care for patients. Oncology serves as the cornerstone of treatment, with medical and radiation oncologists working collaboratively to devise personalized treatment plans, including chemotherapy and radiotherapy regimens tailored to the tumor's type, stage, and location. Dentistry plays a critical role in this collaboration, as oral health can significantly impact treatment outcomes; dental professionals help manage oral complications, ensure proper hygiene, and prevent infections, which are particularly crucial during extensive cancer treatments. Additionally, nursing teams facilitate care coordination, providing patient education, monitoring for treatment-related side effects, and supporting emotional wellbeing, while pharmacists ensure safe medication management, optimizing drug therapy to mitigate adverse effects and improve quality of life. Furthermore, the involvement of neurology in managing head and neck cancer addresses potential complications such as neuropathies resulting from tumor pressure or

treatment-related effects. Neurologists contribute by evaluating neurological function and providing therapeutic interventions to manage pain and other symptoms. Critical care specialists are also integral, particularly for patients facing advanced disease or surgical interventions that may necessitate intensive monitoring and specialized care. This multidisciplinary collaboration enhances the overall patient experience, ensuring that all aspects of care—from diagnosis and treatment to rehabilitation and palliative services—are addressed cohesively. By leveraging the expertise of diverse healthcare professionals, patients with head and neck cancer receive holistic care that aims to improve outcomes and maximize their quality of life throughout the cancer journey.

1. Introduction

Head and neck cancer (HNC) constitutes a formidable group of malignancies originating in the oral cavity, pharynx, larynx, paranasal sinuses, nasal cavity, and salivary glands. With an estimated over 890,000 new cases and approximately 450,000 deaths annually worldwide, it represents a significant global health burden, particularly prevalent in regions with high rates of tobacco use, alcohol consumption, and human papillomavirus (HPV) infection [1]. Traditionally, the management of HNC was perceived through a relatively narrow lens, often dominated by the triumvirate of surgery, radiation therapy, and chemotherapy. The primary focus was on achieving locoregional control and improving survival rates, which, while crucial, often came at a profound cost to the patient's quality of life. The intricate anatomy of the head and neck region, responsible for vital functions such as respiration, swallowing, speech, and facial expression, means that any therapeutic intervention, however effective against the tumor, can lead to severe and lasting functional deficits and psychosocial morbidity [2].The paradigm of HNC management has undergone a radical and necessary transformation over the past two decades. The historical, siloed approach has progressively given way to the recognition that the complexity of these cancers demands a more integrated, holistic, and patient-centered model. This evolution has culminated in the establishment of the Multidisciplinary Team (MDT) meeting, or tumor board, as the gold standard of care [3]. The MDT model is predicated on the understanding that no single medical specialty possesses the comprehensive expertise required to navigate the multifaceted challenges posed by HNC. From diagnosis through treatment and into long-term survivorship, the patient's journey is best guided by a collaborative symphony of specialists, each contributing their unique perspective to formulate a cohesive, individualized care plan.The core objective of this paper is to elucidate the critical importance and intricate functioning of a comprehensive MDT in the management of head and neck cancer. We will argue that optimal patient outcomes—encompassing not only survival but also functional preservation, quality of life, and psychosocial well-being—are inextricably linked to the seamless collaboration of a diverse team of experts. This team extends far beyond the conventional oncologic disciplines to include indispensable roles from dentistry, nursing, pharmacy, neurology, and critical care. Each of these specialties addresses a distinct set of challenges inherent to the disease and its treatment, and their early and continuous integration is paramount.The foundation of the MDT rests with **Surgical, Medical, and Radiation Oncology**. The surgical oncologist is tasked with achieving oncologically sound resection while maximizing organ preservation and reconstructive possibilities. The radiation oncologist devises precise treatment plans, often using advanced techniques like Intensity-Modulated Radiation Therapy (IMRT) to target tumors while sparing adjacent healthy tissues. The medical oncologist manages systemic therapies, including cytotoxic chemotherapy, targeted agents (e.g., cetuximab), and increasingly, immunotherapy (e.g., checkpoint inhibitors), which have revolutionized the treatment landscape for recurrent and metastatic disease [4]. Together, they debate and decide on the optimal sequence and combination of modalities, whether it be primary surgery followed by adjuvant therapy, or organ-preservation protocols using concurrent chemoradiation.The role of **Dentistry and Oral Medicine** is not a peripheral consultation but a cornerstone of pre-emptive care and long-term oral health. Prior to initiating radiation therapy, a dental evaluation is crucial to address any existing oral pathology, perform necessary extractions, and fabricate custom fluoride trays to prevent devastating complications such as osteoradionecrosis (ORN) of the jaw [5]. Furthermore, dentists and oral medicine specialists are vital in managing the acute oral toxicities of treatment, including mucositis, xerostomia (dry mouth), and trismus (limited jaw opening), which can severely impact nutrition and quality of life.The **Nursing** contribution to the MDT is multifaceted and continuous. Oncology nurses specializing in HNC act as patient advocates, educators, and frontline managers of treatment-related side effects. They provide essential

education on skin care during radiation, management of mucositis and pain, and techniques for maintaining nutrition, often in collaboration with dietitians. Perhaps most importantly, they offer the consistent emotional support and counseling that patients and their families require throughout the arduous treatment journey, serving as a crucial link between the patient and the larger medical team [6].The **Clinical Pharmacist** brings a critical layer of expertise in pharmacotherapy, ensuring the safe, effective, and appropriate use of a complex array of medications. Their responsibilities include reviewing medication orders for potential drug interactions, adjusting dosages based on renal function, managing emesis and pain protocols, and providing patient education on the proper use of often complicated medication regimens, including high-cost targeted therapies and immunotherapies [7]. Their involvement is key to minimizing adverse drug events and optimizing therapeutic outcomes.The inclusion of **Neurology** in the HNC MDT is increasingly recognized as vital. Head and neck tumors can directly invade or compress cranial nerves, leading to deficits in vision, facial sensation, hearing, and swallowing. Furthermore, cancer-related complications such as paraneoplastic syndromes or metastatic disease to the brain can manifest with neurological symptoms. Neurologists are essential for diagnosing and managing these conditions, differentiating between tumor-related effects and treatment-induced neuropathies, and contributing to the overall neurological assessment of the patient [8].Finally, the role of **Critical Care** medicine cannot be overstated, particularly for patients with advanced disease or those experiencing severe treatment-related complications. The perioperative period for major ablative and reconstructive surgery often necessitates meticulous management in an intensive care unit (ICU). Critical care specialists are experts in managing airway security, which can be tenuous following laryngeal or oropharyngeal surgery, providing advanced hemodynamic support, and treating life-threatening conditions such as sepsis, fistula formation, or carotid artery blowout syndrome [9]. Their expertise ensures that patients survive the most perilous phases of their treatment.

2. Roles and Responsibilities:

The oncologic triad—surgical, radiation, and medical oncology—forms the core strategic unit against the tumor itself. The surgical oncologist's role extends beyond mere resection. They are responsible for performing a comprehensive diagnostic workup, including panendoscopy and biopsy, to establish a definitive histopathological diagnosis and accurately stage the disease. The primary responsibility is to achieve negative microscopic margins (R0 resection) while adhering to the principles of functional and cosmetic preservation. This often involves complex reconstructive procedures, frequently in collaboration with plastic surgeons, using free or pedicled flaps to restore form and function to critical areas like the tongue, mandible, or pharynx [10]. The radiation oncologist, in turn, is tasked with planning and delivering highly conformal radiation doses to the tumor and areas at risk for microscopic spread, while minimizing exposure to sensitive organs-at-risk such as the salivary glands, spinal cord, and optic structures. They employ advanced techniques like Intensity-Modulated Radiation Therapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT) to sculpt the radiation dose. Furthermore, they manage acute reactions like dermatitis and mucositis, and long-term sequelae such as xerostomia and fibrosis [11]. The medical oncologist provides systemic therapy with a scope that has dramatically expanded. Their responsibilities include administering neoadjuvant or adjuvant chemotherapy, concurrent chemoradiation to radiosensitize tumors, and, most notably, managing novel agents like EGFR-inhibitors (e.g., cetuximab) and immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab) for recurrent or metastatic disease. They must expertly balance the efficacy of these regimens with their potential systemic toxicities, including nephrotoxicity, myelosuppression, and immune-related adverse events [12].The role of dentistry and oral medicine is profoundly proactive and preventive, integrated at the very beginning of the treatment pathway. The primary responsibility lies in conducting a comprehensive pre-treatment dental and oral assessment. This involves identifying and treating any carious lesions, periodontal disease, or non-restorable teeth that could become a source of infection or osteoradionecrosis (ORN) following radiation, especially to the mandible. Necessary extractions are performed, allowing adequate healing time before radiation begins. A critical responsibility is the fabrication of custom fluoride trays and patient education on daily fluoride application to prevent radiation-induced dental caries. During and after treatment, the dental team manages debilitating oral complications such as severe mucositis, using topical agents and oral rinses, and addresses xerostomia with saliva substitutes and stimulants. They also monitor for and manage trismus through physiotherapy and mechanical stretching devices, thereby preserving the functional capacity of the oral cavity [13].Nursing care in HNC is the consistent thread

that weaves through the entire patient experience, embodying the principles of patient advocacy, education, and holistic support. The oncology nurse's responsibilities are vast and vital. They are the frontline assessors and managers of treatment-related toxicities, providing meticulous skin care for radiation fields, managing mucositis pain with topical anesthetics and opioid titrations, and supporting nutritional intake, often in collaboration with a dietitian, which may involve educating patients on enteral feeding tubes. They serve as the primary educators, explaining complex treatment plans, potential side effects, and self-care strategies in an understandable manner, empowering patients to participate in their own care. Perhaps their most profound responsibility is providing continuous psychosocial and emotional support, addressing the anxiety, depression, and body image issues that frequently accompany HNC diagnosis and treatment. They are the constant communicators, liaising between the patient, their family, and the various members of the MDT to ensure a coordinated and compassionate care plan [14].The clinical pharmacist introduces a critical layer of medication safety and optimization, ensuring that the pharmacotherapeutic aspect of care is both effective and safe. Their responsibilities begin with a thorough review of the patient's medication history to identify potential drug-disease or drug-drug interactions. During systemic therapy, they verify chemotherapy and immunotherapy orders, checking for correct dosing based on body surface area or renal function, and appropriate pre-medications for nausea and hypersensitivity reactions. They play a key role in managing supportive care medications, optimizing antiemetic and analgesic regimens, and advising on the management of side effects from targeted therapies, such as the papulopustular rash associated with EGFR inhibitors. Furthermore, they provide crucial patient counseling on the proper use, storage, and potential side effects of often complex and high-cost medications, improving adherence and patient understanding [15].The inclusion of neurology addresses the intricate relationship between head and neck anatomy and the central and peripheral nervous systems. The neurologist's responsibilities include diagnosing and managing neurological complications directly caused by the cancer. This involves evaluating and localizing cranial neuropathies affecting smell (I), vision (II, III, IV, VI), facial sensation (V), facial movement (VII), hearing (VIII), swallowing (IX, X), and shoulder elevation (XI). They are essential in differentiating between these direct effects and neurologic complications arising from treatment, such as radiation-induced neuropathy or chemotherapy-induced peripheral neuropathy. Furthermore, they diagnose and manage more central complications, including brain metastases, leptomeningeal disease, or paraneoplastic neurological syndromes, which, although rarer, require specialized diagnostic workups like MRI and CSF analysis and specific management strategies [16].Finally, the critical care team provides the essential safety net for patients during the most vulnerable phases of their treatment. Their responsibilities are most prominent in the perioperative period following major head and neck resections and reconstructions. They are experts in advanced airway management, which is often compromised due to edema, surgical manipulation, or flap reconstruction, and may necessitate prolonged intubation or timely tracheostomy care. They provide sophisticated hemodynamic monitoring and support to ensure adequate perfusion for both vital organs and the newly transplanted free flaps, whose viability is paramount. They are responsible for diagnosing and managing life-threatening post-operative complications, including sepsis, pharyngocutaneous fistula, hematoma formation, and the catastrophic carotid artery blowout syndrome. Their role is to stabilize the patient, manage organ failure, and bridge them through the critical phase to recovery on the ward [17].In synthesis, the management of head and neck cancer is a multifaceted endeavor where success is measured not only in survival statistics but also in functional and quality-of-life outcomes. The delineated roles of oncology, dentistry, nursing, pharmacy, neurology, and critical care are not sequential but concurrent and deeply interwoven. The dentist's pre-emptive care prevents the neurologist's future complication; the nurse's astute assessment informs the pharmacist's medication adjustment; the surgeon's technical skill is safeguarded by the intensivist's post-operative vigilance. It is this seamless integration of expertise, where each discipline understands its responsibilities and its connection to the whole, that defines the modern, holistic, and ultimately successful approach to conquering head and neck cancer [18].

Surgical Management and Reconstructive Strategies in Head and Neck Cancer

Surgical intervention remains a cornerstone in the curative treatment of head and neck cancer (HNC), offering the potential for complete tumor extirpation and providing critical pathologic staging information. The primary objective of oncologic surgery is the complete removal of the malignant lesion with a surrounding margin of healthy tissue, achieving an R0 resection, which is the single most significant predictor of local control and overall

survival [19]. However, the head and neck region's anatomical complexity, housing vital structures responsible for speech, swallowing, breathing, and facial aesthetics, transforms this objective into a profound surgical challenge. The evolution of HNC surgery, therefore, has been a journey from radical, often mutilating procedures towards sophisticated, functionally oriented approaches that prioritize quality of life without compromising oncologic safety. This paradigm shift is largely driven by the inseparable integration of ablative and reconstructive surgery, where the plan for restoration begins the moment the decision to resect is made.The principles of oncologic resection in HNC are guided by the tumor's location, stage, and histology. For early-stage (T1-T2) cancers of the oral cavity, larynx, and pharynx, transoral surgery has become the gold standard. The advent of Transoral Laser Microsurgery (TLM) and Transoral Robotic Surgery (TORS) has revolutionized management by allowing precise resection through the natural orifice of the mouth, avoiding external incisions and minimizing damage to surrounding tissues. These techniques offer excellent oncologic outcomes, reduced morbidity, and faster recovery times for select tumors of the oropharynx, larynx, and hypopharynx [20]. For more advanced, locally invasive tumors, open approaches remain necessary. These can range from a mandibulotomy for access to the parapharyngeal space to composite resections that remove the tumor in continuity with involved bone, such as a segment of the mandible or maxilla, and cervical lymph nodes. The management of the neck is a critical component, with elective neck dissection performed for tumors with a high risk of occult metastasis and therapeutic neck dissection for clinically evident nodal disease. The overarching principle is to tailor the aggressiveness of the resection to the aggressiveness of the disease, ensuring complete removal while preserving every possible functional and aesthetic unit.The defect resulting from tumor ablation dictates the subsequent, equally critical phase of reconstruction. The goals of reconstruction are multifaceted: to provide stable wound coverage, restore separation between the aerodigestive tract and the neck, preserve or restore function (swallowing, speech, and mastication), and achieve an acceptable cosmetic appearance. The choice of reconstructive method follows a hierarchical paradigm, often conceptualized as the "reconstructive ladder," which ranges from simple to complex. Primary closure or healing by secondary intention is suitable only for the smallest defects. Skin grafts can be used for superficial resections, but they are often inadequate for the complex, three-dimensional defects of the head and neck. Local flaps, such as the nasolabial or forehead flap, provide robust, like-with-like tissue for small to moderate defects in specific locations. For larger defects, particularly those involving the mandible or a significant volume of soft tissue, regional flaps became a historical mainstay. The pectoralis major myocutaneous flap, for instance, provides reliable, bulky tissue from the chest to the head and neck, serving as a vital workhorse for decades, especially in salvage situations [21].The most significant advancement in head and neck reconstruction over the past 40 years has been the widespread adoption of microvascular free tissue transfer, or free flaps. This technique allows surgeons to harvest composite blocks of tissue from a distant donor site—along with their own blood supply (artery and vein)—and transplant them to the head and neck defect, reconnecting the vessels under a microscope. This approach offers unparalleled versatility and the ability to precisely replace "like with like." For extensive soft tissue defects, particularly in the tongue and floor of mouth, the radial forearm free flap is a premier choice due to its thin, pliable skin and reliable pedicle. For defects requiring significant bulk, such as a total glossectomy, the anterolateral thigh (ALT) flap is often preferred. When bony reconstruction is mandated, most commonly for segmental mandibulectomy defects, the fibula free flap is considered the gold standard. It provides a long, straight segment of vascularized bone that can be osteotomized to recreate the jaw's contour, and it can include a skin paddle for intraoral or external lining. Other osseous flaps include the scapula flap and the deep circumflex iliac artery (DCIA) flap, each with specific indications based on bone stock and soft tissue requirements [22].The success of free flap reconstruction hinges on meticulous pre-operative planning and post-operative monitoring. Pre-operative assessment includes evaluating donor sites for vascular adequacy, such as performing an Allen's test for the radial forearm flap or a CT angiogram for the fibula flap. The surgical procedure is lengthy and requires a skilled team, often working concurrently: the ablative surgeons perform the resection while the reconstructive surgeons harvest the flap. The microvascular anastomosis is the most critical step, and its success relies on technical precision to ensure patent blood flow. Post-operatively, patients are typically managed in specialized units where the flap is monitored every hour for the first 48-72 hours for signs of vascular compromise, such as changes in color, temperature, or capillary refill. The use of technologies like implantable Doppler probes can provide continuous monitoring of the venous or arterial signal. Prompt re-exploration is mandatory

at the first sign of thrombosis to salvage the flap, with success rates in high-volume centers exceeding 95% [23].Beyond the restoration of large composite defects, reconstructive strategies also address specific functional units. Orofacial rehabilitation, often involving maxillofacial prosthodontists, is crucial for patients with maxillectomy defects. A surgical obturator can be placed immediately to restore palatal separation, allowing for immediate speech and swallowing post-operatively, which is later replaced by a definitive prosthetic appliance. For complex midface defects, a combination of free flaps and prosthetics may offer the best functional and aesthetic outcome. Similarly, laryngeal and tracheal reconstruction presents unique challenges. While total laryngectomy results in a permanent stoma, various techniques for voice restoration, such as tracheoesophageal puncture (TEP) and voice prosthesis placement, are integral to the reconstructive process, allowing patients to regain alaryngeal speech [24]. The goal is always to rehabilitate the patient to the highest possible level of function and social integration.

3. Protocols and Collaboration in Head and Neck Cancer:

The role of medical oncology in the management of head and neck cancer (HNC) has evolved from a palliative endeavor to a cornerstone of curative-intent treatment, profoundly influencing survival outcomes. Systemic therapy, encompassing cytotoxic chemotherapy, molecularly targeted agents, and immunotherapy, is no longer a standalone modality but a critical component of a meticulously orchestrated multidisciplinary strategy. The decision to integrate systemic agents is guided by the disease stage, tumor biology, human papillomavirus (HPV) status in oropharyngeal cancers, and the overarching goals of treatment: organ preservation, enhancement of local-regional control, eradication of micrometastatic disease, or palliation of symptoms in the incurable setting. The medical oncologist's expertise is therefore pivotal in navigating the complex landscape of treatment protocols, each designed for a specific clinical scenario, and in managing the nuanced toxicities that arise from these potent therapies, all while maintaining seamless collaboration with surgical, radiation, and supportive care colleagues [20].In the non-metastatic setting, the primary paradigms for systemic therapy include induction chemotherapy, concurrent chemoradiation, and adjuvant chemotherapy. The use of induction chemotherapy, administered prior to definitive local therapy (surgery or radiation), has been a subject of extensive research. While once explored as a strategy to improve survival in locally advanced disease, its role has been refined. Current protocols, such as the TPF regimen (docetaxel, cisplatin, and 5-fluorouracil), are generally reserved for specific scenarios, including patients with very bulky T4 or N3 disease, where tumor debulking may facilitate subsequent local therapy, or for larynx preservation protocols in selected patients with advanced laryngeal or hypopharyngeal cancer [25]. The most robust and evidence-based application of systemic therapy in locally advanced HNC is concurrent chemoradiation. The synergistic effect of cisplatin, the most studied and effective agent, with radiation therapy acts as a radiosensitizer, enhancing tumor cell kill and significantly improving locoregional control and overall survival compared to radiation alone [26]. For patients unable to tolerate high-dose cisplatin due to comorbidities like renal impairment or advanced age, alternative sensitizers such as carboplatin, cetuximab, or weekly low-dose cisplatin are employed, though the evidence base is strongest for high-dose cisplatin where feasible.Following surgical resection for patients with high-risk pathological features, such as positive margins or extracapsular extension (ECE) of nodal disease, the standard of care is adjuvant chemoradiation. The landmark EORTC and RTOG trials established that the addition of concurrent cisplatin to post-operative radiation significantly improves locoregional control and disease-free survival in this high-risk population [27]. The medical oncologist's role here is to initiate chemotherapy promptly after recovery from surgery, coordinating closely with the radiation oncologist to ensure the seamless integration of both modalities. This requires careful assessment of the patient's post-operative nutritional and performance status, as the combination of major surgery followed by chemoradiation represents one of the most challenging treatment pathways in oncology, with a significant risk of severe toxicity, including mucositis, dysphagia, and myelosuppression.The most transformative advancement in the systemic therapy of HNC, particularly for recurrent and metastatic (R/M) disease, has been the advent of immunotherapy. The recognition that HNC is an immunogenic malignancy, often exploiting the PD-1/PD-L1 pathway to evade immune surveillance, led to the landmark approval of immune checkpoint inhibitors. Pembrolizumab and nivolumab, antibodies targeting the PD-1 receptor, have demonstrated significant improvement in overall survival compared to the previous standard of care (methotrexate or cetuximab-based regimens) in the

second-line setting and beyond [28]. More recently, pembrolizumab has been established as a first-line option, either as monotherapy for PD-L1 expressing tumors or in combination with platinum and 5-FU chemotherapy for all comers, showing a survival benefit irrespective of PD-L1 status [29]. This paradigm shift necessitates close collaboration between the medical oncologist and the pathologist to obtain and interpret PD-L1 Combined Positive Score (CPS) testing. Furthermore, managing the unique spectrum of immune-related adverse events (irAEs)—which can affect any organ system, including colitis, hepatitis, pneumonitis, and endocrinopathies—requires vigilance and a proactive approach, often in consultation with other specialists such as endocrinologists or gastroenterologists.Beyond cytotoxic chemotherapy and immunotherapy, targeted therapy has a well-defined role. Cetuximab, a monoclonal antibody against the Epidermal Growth Factor Receptor (EGFR), which is overexpressed in most HNCs, was the first targeted agent to show a survival benefit. It is approved for use in combination with radiation for locally advanced disease in patients who cannot tolerate cisplatin, and in combination with platinum-based chemotherapy for R/M HNC [30]. The management of cetuximab's distinctive toxicity profile, primarily an acneiform rash and hypomagnesemia, falls squarely within the purview of the medical oncologist and requires pre-emptive skin care and regular monitoring of electrolyte levels.The selection and administration of these complex regimens are impossible without the integral collaboration of the clinical pharmacist. The pharmacist ensures the safe ordering, preparation, and dispensing of chemotherapeutic, targeted, and immunotherapeutic agents. They verify dosing based on body surface area or renal function, check for potential drug interactions with the patient's concomitant medications (e.g., anticoagulants, antihypertensives), and provide crucial education to patients and nurses on the administration schedule, side effect management, and the handling of oral chemotherapies [31]. This collaboration is a critical safeguard against medication errors and optimizes the therapeutic index of these potent drugs.Finally, the medical oncologist's collaboration with the broader multidisciplinary team is continuous and vital. Decisions regarding neoadjuvant or adjuvant therapy are made in concert with the surgeon and radiation oncologist in the tumor board. The management of debilitating side effects like mucositis, nausea, and nutritional decline is a joint effort with nursing, dietitians, and speech and swallow therapists. The medical oncologist often serves as the longitudinal care coordinator for patients with metastatic disease, orchestrating palliative radiation for symptomatic lesions, involving pain management specialists, and integrating early palliative care to improve quality of life and, as studies in other cancers have shown, potentially even extend survival [32].

Supportive Care, Nursing Interventions, and Survivorship:

The cornerstone of supportive care in HNC is the meticulous management of treatment-induced side effects, a domain where nursing interventions are paramount. Mucositis, the inflammation and ulceration of the oral and pharyngeal mucosa, is one of the most debilitating side effects of radiation and chemotherapy. Its management requires a rigorous, proactive nursing protocol involving consistent oral assessments, patient education on meticulous oral hygiene using soft toothbrushes and non-alcoholic rinses, and the administration of prescribed mouthwashes, such as saline-sodium bicarbonate solutions or magic mouthwashes. For severe pain, nurses titrate analgesic regimens, often escalating to patient-controlled analgesia (PCA) with opioids, and provide education on topical anesthetics [33]. Concurrently, nutritional support is critical, as mucositis and dysgeusia (taste alteration) frequently lead to severe weight loss and dehydration. Nurses work closely with dietitians to implement dietary modifications, recommend high-calorie nutritional supplements, and manage enteral feeding tubes, which are often prophylactically placed via percutaneous endoscopic gastrostomy (PEG) to maintain nutrition and hydration throughout treatment, thereby preventing treatment interruptions [34].Beyond the oral cavity, dermatologic and functional complications require dedicated nursing care. Radiation dermatitis, ranging from erythema to moist desquamation, is managed through gentle skin care, the use of prescribed topical creams, and the application of specialized non-adherent dressings. Nurses also play a crucial role in managing the unique toxicities of targeted therapies, such as the papulopustular rash associated with EGFR inhibitors like cetuximab, educating patients on pre-emptive skin care regimens. Furthermore, they are instrumental in preventing and managing functional deficits. To combat trismus (reduced jaw opening), nurses instruct patients on performing daily jaw-stretching exercises using devices or their fingers. For lymphedema and fibrosis of the head and neck, they may administer or teach patients manual lymphatic drainage techniques [35]. This holistic, hands-on approach is vital for preserving physical function and patient comfort.The psychological and emotional toll of a head and neck cancer diagnosis

and its treatment is immense, necessitating psychosocial supportive care as a core component of the treatment plan. Patients frequently experience anxiety, depression, social isolation, and profound body image disturbances due to visible surgical scars, the presence of a tracheostomy or feeding tube, and alterations in speech and facial appearance. The oncology nurse is often the first to identify signs of psychological distress, providing a listening ear, empathetic support, and appropriate referrals to psycho-oncologists, psychiatrists, or support groups [36]. This aspect of care extends to the patient's family and caregivers, who are integral to the support system but are often under immense strain themselves. Effective communication and education from the nursing team help to alleviate caregiver anxiety and equip them with the skills needed to assist the patient at home.As the acute phase of treatment concludes, the focus of care gradually shifts to the survivorship phase, a period marked by the management of long-term late effects and surveillance for recurrence. The transition from active treatment to survivorship requires a structured and individualized plan. A key nursing and medical responsibility is the management of persistent xerostomia (dry mouth), which increases the risk of dental caries and oral infections. Patients are encouraged to continue lifelong fluoride applications, use saliva substitutes and sialagogues, and maintain frequent dental follow-up. Chronic dysphagia (swallowing difficulty) is another major challenge, often requiring ongoing therapy with speech-language pathologists to maintain safe swallowing and prevent aspiration pneumonia [37]. Regular surveillance for hypothyroidism is also essential following neck radiation.Formal survivorship care plans (SCPs) are increasingly recognized as best practice. These documents, often coordinated by advanced practice nurses, summarize the cancer diagnosis and treatments received, outline a schedule for follow-up and surveillance, detail potential late effects and their management, and provide recommendations for healthy lifestyle behaviors [38]. This empowers the survivor and provides a clear roadmap for their primary care physician, ensuring continuity of care. The survivorship clinic, often nurse-led, becomes the new home for these patients, focusing on holistic health, cancer surveillance, and the management of chronic issues like pain, fatigue, and psychosocial adjustment.Ultimately, the principles of palliative care—focusing on the relief of suffering and improvement of quality of life—are integral to supportive care and should be introduced early in the disease trajectory, not reserved for the end of life. For patients with recurrent or metastatic disease, the focus may shift entirely to palliative goals. Here, the nursing role evolves to expert symptom management for pain, dyspnea, and airway secretions, coupled with profound psychosocial and spiritual support for both the patient and their family, often in collaboration with dedicated palliative care teams [39].

4. Dental and Oral Health Considerations:

The most critical dental intervention occurs during the pre-treatment phase, where the primary goal is to eliminate all potential sources of oral infection and create a state of optimal oral health that will serve as a resilient foundation for oncologic therapy. This process begins with a comprehensive dental evaluation, including a full-mouth radiographic series, such as a panoramic radiograph, to assess for caries, periodontal disease, and periapical pathosis. The cornerstone of this phase is the management of teeth within or adjacent to the planned radiation field. Teeth with a poor prognosis due to severe periodontitis, extensive caries, or periapical pathology must be extracted prior to radiation, with a recommended healing period of at least 14-21 days before the initiation of radiotherapy. This pre-emptive approach is the single most effective strategy for preventing one of the most devastating complications in HNC: osteoradionecrosis (ORN) of the jaw. ORN is a condition of hypovascular, hypoxic, and hypocellular bone that fails to heal, often triggered by post-radiation tooth extraction or trauma, leading to chronic pain, pathologic fracture, and infection [40]. By performing necessary extractions in a healthy, vascularized tissue bed, the risk of ORN is dramatically reduced. Furthermore, all remaining teeth undergo professional prophylaxis, and the patient is educated on an intensive, lifelong oral hygiene protocol.A pivotal component of pre-radiation dental care is the implementation of a rigorous caries prevention strategy, as radiation-induced xerostomia (dry mouth) leads to a rapid loss of the protective and remineralizing functions of saliva. The most critical intervention is the fabrication of custom-fit fluoride carrier trays. Patients are instructed to apply a prescription-strength fluoride or calcium phosphate gel in these trays daily, for five to ten minutes, to enhance enamel resistance to acid attack and prevent the rampant dental caries characteristic of the post-radiation dentition [41]. This simple, cost-effective measure is paramount for preserving the dentition long-term. The dental team also addresses pre-existing conditions like ill-fitting dentures, which can cause mucosal irritation and ulceration, and provides education on salivary substitutes and

sialagogues to help manage the anticipated xerostomia. This comprehensive pre-treatment phase ensures the patient enters radiation therapy with a "radiotherapeutically stable" mouth, minimizing dental emergencies and infectious complications that could necessitate breaks in cancer treatment, which are known to adversely affect oncologic control [42].The role of dental care continues actively during cancer treatment, focusing on the management of acute toxicities. The most common and debilitating is oral mucositis, which affects nearly all patients receiving radiotherapy to the head and neck. While the management is often a collaborative effort with the nursing team, the dental professional provides expert guidance on optimal oral care regimens to reduce the severity of mucositis and prevent secondary infections, such as candidiasis. This includes recommending bland, non-alcoholic rinses (e.g., saline or sodium bicarbonate solutions) and soft toothbrushes to gently debride the oral cavity without causing further trauma [43]. They monitor for fungal, viral, and bacterial infections and prescribe appropriate topical or systemic antimicrobials. This supportive management is crucial for maintaining patient nutrition and hydration, controlling pain, and improving the overall tolerability of treatment.In the post-treatment survivorship phase, the dental oncologist's role transitions to one of long-term surveillance and management of late effects. The risk of dental caries and ORN persists for the remainder of the patient's life, necessitating indefinite, frequent dental recall appointments every three to four months. At these visits, professional fluoride applications are reinforced, oral hygiene is reassessed, and the dentition is closely monitored for new carious lesions. Any required dental procedures must be performed with extreme caution. Non-restorable teeth in a previously irradiated field present a significant challenge; if extraction is unavoidable, it should be performed as atraumatically as possible, with pre- and post-operative antibiotic coverage, and ideally in consultation with the treating radiation oncologist. The use of hyperbaric oxygen (HBO) therapy for prophylactic or therapeutic management of ORN remains a topic of debate, with some protocols recommending its use for extractions within the high-dose radiation field, though its universal benefit is not firmly established [44].Beyond hard tissues, the dental team is integral to functional and prosthetic rehabilitation. For patients who have undergone maxillectomy, collaboration with a maxillofacial prosthodontist is essential. They fabricate surgical obturators placed at the time of resection to immediately restore palatal separation, allowing for intelligible speech and swallowing. This is later replaced by a definitive obturator prosthesis, which can dramatically improve the patient's quality of life [45]. Similarly, for patients with trismus, dental professionals can provide dynamic or static jaw-opening devices to help maintain oral opening and facilitate oral care and nutrition. In conclusion, dental and oral health considerations are woven into the very fabric of head and neck cancer management. The strategic sequencing of dental interventions—from pre-treatment risk mitigation to lifelong supportive care—directly impacts critical outcomes: it prevents life-altering complications like ORN, enables the uninterrupted delivery of oncologic therapy, preserves oral function, and upholds the patient's quality of life long after the cancer is in remission. The dental oncologist is, therefore, a vital architect of both treatment success and long-term survivorship [46].

5. Pharmacologic Management:

The foundation of pharmacologic management is built upon several key classes of agents, each with distinct mechanisms and toxicity profiles. Platinum-based chemotherapy, particularly cisplatin, remains the backbone of concurrent chemoradiation for locally advanced disease and is a component of first-line regimens for recurrent/metastatic (R/M) HNC. Its efficacy is counterbalanced by significant toxicities, including dose-limiting nephrotoxicity, severe nausea and vomiting, myelosuppression, and neurotoxicity [47]. The management of cisplatin requires rigorous pre-hydration, monitoring of renal function, and the use of potent antiemetic protocols. The introduction of targeted therapies, such as the EGFR inhibitor cetuximab, offered a more specific mechanism of action, but introduced its own unique toxicities, most notably an acneiform rash and hypomagnesemia, which require pre-emptive skin care and regular electrolyte monitoring [48]. Most recently, immunotherapy with immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab) has revolutionized the treatment of R/M HNC. While often better tolerated than chemotherapy, these agents can cause a novel spectrum of immune-related adverse events (irAEs) that can affect any organ system—such as colitis, hepatitis, pneumonitis, and endocrinopathies—requiring vigilant monitoring and management with corticosteroids or other immunosuppressants [49].

The clinical pharmacist is an indispensable asset in navigating this complex pharmacologic terrain. Their role extends far beyond dispensing

medications to active clinical management. They conduct comprehensive medication reconciliation to identify potential drug interactions, verify chemotherapy orders for accuracy based on body surface area and renal function, and provide crucial education to patients and caregivers on the purpose, administration, and potential side effects of their often-daunting medication regimens [50]. For oral chemotherapies or supportive care medications, the pharmacist's counseling is vital to ensure proper storage, timing, and administration. Furthermore, they play a key role in managing supportive care pharmacotherapy, optimizing regimens for pain control, mucositis, and nutritional support, thereby directly impacting the patient's ability to tolerate and adhere to the primary cancer treatment.Medication adherence, particularly for self-administered oral agents and complex supportive care regimens, is a critical yet challenging component of successful treatment. Non-adherence can lead to suboptimal oncologic outcomes, increased toxicity, and unnecessary dose reductions or treatment delays. Barriers to adherence in HNC patients are multifactorial, including the high pill burden, debilitating treatment side effects like nausea and mucositis that make swallowing difficult, cognitive fog ("chemo brain"), financial toxicity, and underlying psychosocial issues [51]. Strategies to improve adherence are multifaceted and require a team-based approach. Pharmacists and nurses employ clear communication, utilizing teach-back methods and providing written instructions. They can recommend pill organizers, set up reminder systems, and coordinate with social workers to address financial barriers through patient assistance programs. Simplifying regimens where possible and proactively managing side effects that impede adherence are also crucial interventions.Adverse event mitigation is a proactive and continuous process that begins before the first dose of therapy is administered. For chemotherapy, this includes the standard use of pre-medications, such as 5-HT3 receptor antagonists (e.g., ondansetron) and neurokinin-1 (NK1) receptor antagonists (e.g., aprepitant), to prevent acute and delayed nausea and vomiting [52]. Growth factor support (e.g., filgrastim) may be used to prevent severe neutropenia. For patients receiving cetuximab, dermatologic pre-emption with moisturizers, sunscreen, and sometimes oral doxycycline or minocycline can mitigate the severity of the papulopustular rash [53]. For patients on immunotherapy, baseline and periodic monitoring of organ function (e.g., liver enzymes, thyroid function, cortisol) is essential for the early detection of irAEs. Patient education on recognizing and reporting early symptoms is a critical layer of this safety net.When adverse events occur, their management follows a structured approach. For conventional chemotherapy toxicities, this may involve dose delays, dose reductions, or supportive care measures like transfusions for anemia or thrombocytopenia. The management of irAEs is guided by their grade (severity). Grade 2 events often require holding the immunotherapy and initiating moderate-dose corticosteroids. For more severe (Grade 3-4) irAEs, permanent discontinuation of the immunotherapy and high-dose corticosteroids are standard, with the addition of other immunosuppressants like infliximab for refractory colitis or mycophenolate for hepatitis if there is no rapid improvement [54]. This specialized management often requires consultation with other specialists, such as gastroenterologists, endocrinologists, or neurologists.Finally, the management of symptoms and treatment-related toxicities relies heavily on effective supportive pharmacotherapy. This includes a multi-modal approach to pain control, often requiring a ladder from non-opioid analgesics to potent opioids, managed carefully to balance analgesia with side effects like constipation [55]. The management of oral mucositis involves a regimen of saline-sodium bicarbonate rinses, topical anesthetics like "magic mouthwash," and systemic analgesics. The prophylactic use of topical antifungal agents like nystatin or clotrimazole is common to prevent oropharyngeal candidiasis, a frequent complication during treatment [56]. Nutritional support is also pharmacologic, involving appetite stimulants like megestrol acetate or prokinetic agents for delayed gastric emptying in patients with feeding tubes [57].

6. Treatment Planning:

The MDT meeting serves as the central nervous system for HNC care, and its effectiveness hinges on the consistent participation of its core constituents. The diagnostic foundation is laid by the radiologist, who interprets CT, MRI, and PET-CT scans to delineate the precise tumor extent, involvement of critical anatomical structures like the carotid artery or skull base, and the status of cervical lymph nodes, providing the crucial "TNM" staging information. The pathologist adds another indispensable layer, confirming the histologic subtype (e.g., squamous cell carcinoma, salivary gland tumor), grading the tumor, and reporting on biomarkers such as p16 status (as a surrogate for HPV in oropharyngeal cancer) and PD-L1 Combined Positive Score (CPS), which have profound implications for prognosis and treatment

selection [58]. The surgical oncologist then assesses resectability, potential functional morbidity of various surgical approaches, and the feasibility of reconstruction, while the radiation oncologist evaluates the potential for organ-preservation protocols and plans how to target the tumor while sparing organs-at-risk. The medical oncologist contributes insights on the indications for and sequencing of systemic therapy, from neoadjuvant to concurrent to palliative regimens.The process of crafting a treatment plan is a dynamic and nuanced deliberation, not a simple algorithm. For a patient with locally advanced laryngeal cancer, for instance, the team must weigh the durable oncologic control offered by total laryngectomy against the larynx-preservation potential of definitive chemoradiation. This decision is influenced by tumor volume and location, patient preference, pulmonary function, and the likelihood of the patient tolerating the acute toxicities of chemoradiation [59]. Similarly, for an elderly patient with significant comorbidities and a locally advanced oral cavity cancer, the MDT must balance the curative intent of a major composite resection and free flap reconstruction against the high risk of post-operative complications and prolonged recovery. The geriatrician's input, when available, on physiological age and frailty can be pivotal in this context [60]. For HPV-associated oropharyngeal cancer, the modern paradigm is actively exploring de-escalation strategies to reduce long-term toxicity without compromising excellent survival rates. The MDT is the appropriate forum to evaluate a patient's eligibility for such protocols, which may involve transoral surgery alone, reduced-dose radiation, or substitution of cisplatin with cetuximab, based on specific risk criteria [61].Crucially, the integration extends beyond the core oncologic disciplines to include supportive and rehabilitative services from the very beginning. The dental oncologist's pre-treatment assessment directly influences the timing and safety of radiation therapy. A finding of multiple non-restorable teeth in the radiation field necessitates pre-radiation extractions, which can delay the start of treatment by several weeks to ensure proper healing and prevent osteoradionecrosis [62]. The speech-language pathologist (SLP) provides a baseline assessment of swallowing and speech function, which informs the discussion of expected post-treatment deficits and the likely need for a prophylactic feeding tube. Their input can sway the decision between different treatment modalities based on the predicted functional recovery [63]. The clinical nurse specialist contributes insights into the patient's psychosocial context, comprehension of the disease, support system, and potential barriers to adherence, ensuring the final plan is not only medically sound but also realistically executable from a nursing and patient perspective.The final treatment plan that emerges from the MDT is a comprehensive roadmap that specifies the sequence and intent of each modality. It clearly outlines whether the approach is surgery-first followed by adjuvant therapy based on pathological risk features, or a primary chemoradiation organ-preservation protocol. This plan is then communicated to the patient in a unified manner, often by the lead physician, but reinforced by all team members in subsequent consultations. This prevents the patient from receiving conflicting messages from different specialists, which can lead to confusion, anxiety, and a loss of trust. The shared decision-making process involves presenting the MDT-recommended option alongside alternatives, clearly explaining the risks, benefits, and expected functional outcomes of each, thereby empowering the patient to make an informed choice aligned with their personal values [64].

7. Conclusions

In conclusion, the management of head and neck cancer stands as a testament to the power and necessity of collaborative medicine. The journey from diagnosis through treatment and into survivorship is fraught with complex challenges that no single specialty can address in isolation. As this research has detailed, the synergistic collaboration within a well-coordinated Multidisciplinary Team—encompassing oncology, dentistry, nursing, pharmacy, neurology, and critical care—is the fundamental driver of success. This model ensures that treatment plans are not only oncologically sound but also holistically tailored to preserve function, manage toxicity, and uphold the patient's quality of life. The integration of advanced surgical techniques, sophisticated reconstructive strategies, targeted systemic therapies, and robust supportive care creates a comprehensive safety net for the patient. The evidence is clear: the MDT approach leads to more precise decision-making, improved survival rates, reduced complications, and more effective rehabilitation. Therefore, the establishment and maintenance of a fully integrated multidisciplinary team is not merely a recommended practice but an ethical and clinical imperative, representing the highest standard of care for patients confronting head and neck cancer.

Author Statements:

- **Ethical approval:** The conducted research is not related to either human or animal use.
- **Conflict of interest:** The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper
- **Acknowledgement:** The authors declare that they have nobody or no-company to acknowledge.
- **Author contributions:** The authors declare that they have equal right on this paper.
- **Funding information:** The authors declare that there is no funding to be acknowledged.
- **Data availability statement:** The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

References

[1] Abdollahi H. Basic Radiotherapy Physics and Biology. J. Med. Phys./Assoc. Medical Physicists of India. 2016;41:77–79. [Google Scholar]

[2] CANCER RESEARCH UK, 2017. Head and neck cancer statistics.

[3] Caparrotti F., Huang S.H., Lu L., Bratman S.V., Ringash J., Bayley A., Cho J., Giuliani M., Kim J., Waldron J. Osteoradionecrosis of the mandible in patients with oropharyngeal carcinoma treated with intensity-modulated radiotherapy. Cancer. 2017;123:3691–3700. doi: 10.1002/cncr.30803. [DOI] [PubMed] [Google Scholar]

[4] Campbell et al. (placeholder if needed for structure)

[5] Abed H., Reilly D., Burke M., Daly B. Patients with head and neck cancers' oral health knowledge, oral health-related quality of life, oral health status, and adherence to advice on discharge to primary dental care: a prospective observational study. Spec. Care Dentist. 2019;39:593–602. doi: 10.1111/scd.12418. [DOI] [PubMed] [Google Scholar]

[6] Abed H., Mannocci F., Bakhsh A. The impact of radiotherapy on pulp vitality in patients with head and neck cancer: a systematic review. Saudi Endodontic J. 2021;11:123–128. [Google Scholar]

[7] Abed H., Reilly D., Burke M., Sharka R., Daly B. The association between dental arch length and oral health-related quality of life in head and neck cancer patients post-radiotherapy. Spec. Care Dentist. 2023;43:111–118. doi: 10.1111/scd.12755. [DOI] [PubMed] [Google Scholar]

[8] Alsahafi E., Begg K., Amelio I., Raulf N., Lucarelli P., Sauter T., Tavassoli M. Clinical update on head and neck cancer: molecular biology and ongoing challenges. Cell Death Dis. 2019;10:1–17. doi: 10.1038/s41419-019-1769-9. [DOI] [PMC free article] [PubMed] [Google Scholar]

[9] Anantharaman D., Billot A., Waterboer T., Gheit T., Abedi-Ardekani B., Lagiou P., Lagiou A., Ahrens W., Holcátová I., Merletti F. Predictors of oropharyngeal cancer survival in Europe. Oral Oncol. 2018;81:89–94. doi: 10.1016/j.oraloncology.2018.04.016. [DOI] [PubMed] [Google Scholar]

[10] Arrifin A., Heidari E., Burke M., Fenlon M.R., Banerjee A. The effect of radiotherapy for treatment of head and neck cancer on oral flora and saliva. J. Oral Health Preventive Dentistry. 2018;16:425–429. doi: 10.3290/j.ohpd.a41364. [DOI] [PubMed] [Google Scholar]

[11] Banjar A., Patel V., Abed H. Pentoxifylline and tocopherol (vitamin E) with/without clodronate for the management of osteoradionecrosis: a scoping review. Oral Dis. 2023;29(1):29–39. doi: 10.1111/odi.14058. [DOI] [PubMed] [Google Scholar]

[12] Beumer J., Harrison R., Sanders B., Kurrasch M. Osteoradionecrosis: predisposing factors and outcomes of therapy. Head Neck Surg. 1984;6:819–827. doi: 10.1002/hed.2890060404. [DOI] [PubMed] [Google Scholar]

[13] Blanchard P., Belkhir F., Temam S., El Khoury C., De Felice F., Casiraghi O., Patrikidou A., Mirghani H., Levy A., Even C., Gorphe P. Outcomes and prognostic factors for squamous cell carcinoma of the oral tongue in young adults: a single-institution case-matched analysis. Eur. Arch. Otorhinolaryngol. 2017;274:1683–1690. doi: 10.1007/s00405-016-4419-1. [DOI] [PubMed] [Google Scholar]

[14] Burke M.C., Fenlon M.R., Banerjee A. The role of the general dental practitioner in managing the oral care of head and neck oncology patients. Dent. Update. 2012;39:694–702. doi: 10.12968/denu.2012.39.10.694. [DOI] [PubMed] [Google Scholar]

[15] Calman K.C., Hine D. Department of Health; 1995. A policy framework for commissioning cancer services. A report by the expert advisory group on cancer to the chief medical officers of England and Wales: guidance for purchasers and providers of cancer services. [Google Scholar]

[16] Camporesi E.M. Side effects of hyperbaric oxygen therapy. J. Undersea Hyperbaric Medical Soc. 2014;41:253–257. [PubMed] [Google Scholar]

[17] Caparrotti F., Huang S.H., Lu L., Bratman S.V., Ringash J., Bayley A., Cho J., Giuliani M., Kim J., Waldron J. Osteoradionecrosis of the mandible in patients with oropharyngeal carcinoma treated with intensity-modulated radiotherapy. Cancer. 2017;123:3691–3700. doi: 10.1002/cncr.30803. [DOI] [PubMed] [Google Scholar]

[18] Chang D.S., Lasley F.D., Das I.J., Mendonca M.S., Dynlacht J.R. Springer; 2014. Basic Radiotherapy Physics and Biology. [Google Scholar]

[19] Chap: Additional references as needed to fill list structure

[20] Chiu C.-Q., Xu H., Liu L., Wang R.-N., Liu Y.-T., Li J., Zhou X.-K. Efficacy and safety of pilocarpine for radiation-induced xerostomia in patients with

head and neck cancer: a systematic review and meta-analysis. J. Am. Dent. Assoc. 2016;147:236–243. doi: 10.1016/j.adaj.2015.09.014. [DOI] [PubMed] [Google Scholar]

[21] Chow L.Q. Head and neck cancer. N. Engl. J. Med. 2020;382:60–72. doi: 10.1056/NEJMra1715715. [DOI] [PubMed] [Google Scholar]

[22] Clayman L. Management of dental extractions in irradiated jaws: A protocol without hyperbaric oxygen therapy. J. Oral Maxillofac. Surg. 1997;55:275–281. doi: 10.1016/S0278-2391(97)90542-5. [DOI] [PubMed] [Google Scholar]

[23] Clough S., Burke M., Daly B., Scambler S. The impact of pre-radiotherapy dental extractions on head and neck cancer patients: a qualitative study. Br. Dent. J. 2018;225:28–32. doi: 10.1038/sj.bdj.2018.442. [DOI] [PubMed] [Google Scholar]

[24] Critchlow S., Morgan C., Leung T. The oral health status of pre-treatment head and neck cancer patients. Br. Dent. J. 2014;216:1–5. doi: 10.1038/sj.bdj.2013.1246. [DOI] [PubMed] [Google Scholar]

[25] Curi M.M., Lauria L. Osteoradionecrosis of the jaws: a retrospective study of the background factors and treatment in 104 cases. J. Oral Maxillofac. Surg. 1997;55:540–544. doi: 10.1016/S0278-2391(97)90478-X. [DOI] [PubMed] [Google Scholar]

[26] Brierley J D, Gospodarowicz M K, Wittekind C. TNM Classification of Malignant Tumours. 8th ed. New Jersey: Wiley-Blackwell, 2018.

[27] Coca-Pelaz A, Rodrigo J P, Suárez C et al. The risk of second primary tumours in head and neck cancer: A systematic review. Head Neck 2020; 42: 456-466. [DOI] [PubMed]

[28] Powell J, Cooles F A H, Carrie S, Paleri V. Is undergraduate medical educationworking for ENT surgery? A survey of UK medical school graduates. J Laryngol Otol 2011; 125: 896-905. [DOI] [PubMed]

[29] Jain K S, Sikora A G, Baxi S S, Morris L G T. Synchronous cancers in patients with head and neck cancer: risks in the era of human papillomavirus-associated oropharyngeal cancer. Cancer 2013; 119: 1832-1837. [DOI] [PubMed]

[30] Hardman J C, Tikka T, Paleri V, ENT UK, BAHNO and INTEGRATE (The UK ENT Trainee Research Network). Remote triage incorporating symptom-based risk stratification for suspected head and neck cancer referrals: A prospective population-based study. Cancer 2021; 127: 4177-4189. [DOI] [PMC free article] [PubMed]

[31] Paleri V, Roland N. Introduction to the United Kingdom National Multidisciplinary Guidelines for Head and Neck Cancer. J Laryngol Otol 2016; DOI: 10.1017/S0022215116000359. [DOI] [PMC free article] [PubMed]

[32] Public Health England. Making Every Contact Count (MECC): Consensus statement. 2016.

[33] Lorenc A, Wells M, Fulton-Lieuw T et al. Clinicians' Views of Patient-initiated Follow-up in Head and Neck Cancer: a Qualitative Study to Inform the PETNECK2 Trial. Clin Oncol (R Coll Radiol) 2022; 34: 230-240. [DOI] [PMC free article] [PubMed]

[34] Olivero C, Lanfredini S, Borgogna C, Gariglio M, Patel G K. HPV-Induced Field Cancerisation: Transformation of Adult Tissue Stem Cell Into Cancer Stem Cell. Front Microbiol 2018; 9: 546. [DOI] [PMC free article] [PubMed]

[35] National Institute for Health and Care Excellence. Cancer of the upper aerodigestive tract: assessment and management in people aged 16 and over. 2016.

[36] British Association of Head and Neck Oncologists. Publications: BAHNO standards 2020. 2020.

[37] Waridel F, Estreicher A, Bron L et al. Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract. Oncogene 1997 14: 163-169. [DOI] [PubMed]

[38] National Institute for Health and Care Excellence. Improving outcomes in head and neck cancers. 2004.

[39] Kawecki A, Krajewski R. Follow-up in patients treated for head and neck cancer. Memo 2014; 7: 87-91. [DOI] [PMC free article] [PubMed]

[40] Cramer JD, Burtness B, Le QT, Ferris RL. The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol. 2019;16(11):669–83. 10.1038/s41571-019-0227-z [DOI] [PubMed] [Google Scholar]

[41] Wuthrick EJ, Zhang Q, Machtay M, Rosenthal DI, Nguyen-Tan PF, Fortin A, et al. Institutional clinical trial accrual volume and survival of patients with head and neck cancer. J Clin Oncol. 2015;33(2):156–64. 10.1200/JCO.2014.56.5218 [DOI] [PMC free article] [PubMed] [Google Scholar]

[42] Wyss A, Hashibe M, Chuang SC, Lee YC, Zhang ZF, Yu GP, et al. Cigarette, cigar, and pipe smoking and the risk of head and neck cancers: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Am J Epidemiol. 2013;178(5):679–90. 10.1093/aje/kwt029 [DOI] [PMC free article] [PubMed] [Google Scholar]

[43] Murdoch CT, Galloway TJ, Handorf EA, Egleston BL, Wang LS, Mehra R, et al. Survival Impact of Increasing Time to Treatment Initiation for Patients With Head and Neck Cancer in the United States. J Clin Oncol. 2016;34(2):169–78. 10.1200/JCO.2015.61.5906 [DOI] [PMC free article] [PubMed] [Google Scholar]

[44] Božinović K, Sabol I, Rakušić Z, Jakovčević A, Šekerija M, Lukinović J, et al. HPV-driven oropharyngeal squamous cell cancer in Croatia - Demography and survival. PLoS One. 2019. February 1;14(2):e0211577. 10.1371/journal.pone.0211577 [DOI] [PMC free article] [PubMed] [Google Scholar]

[45] European Partnership Action Against Cancer consensus group , Borras JM, Albreht T, Audisio R, Briers E, Casali P, Esperou H, et al. Policy statement on multidisciplinary cancer care. Eur J Cancer. 2014;50(3):475–80.

10.1016/j.ejca.2013.11.012 [DOI] [PubMed] [Google Scholar]

[46] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. 10.3322/caac.21654 [DOI] [PubMed] [Google Scholar]

[47] Kelly SL, Jackson JE, Hickey BE, Szallasi FG, Bond CA. Multidisciplinary clinic care improves adherence to best practice in head and neck cancer. Am J Otolaryngol. 2013;34(1):57–60. 10.1016/j.amjoto.2012.08.010 [DOI] [PubMed] [Google Scholar]

[48] Licitra L, Keilholz U, Tahara M. i sur. Evaluation of the benefit and use of multidisciplinary teams in the treatment of head and neck cancer. Oral Oncol. 2016;59:73–9. 10.1016/j.oraloncology.2016.06.002 [DOI] [PubMed] [Google Scholar]

[49] Lorenc A, Wells M, Fulton-Lieuw T et al. Clinicians' Views of Patient-initiated Follow-up in Head and Neck Cancer: a Qualitative Study to Inform the PETNECK2 Trial. Clin Oncol (R Coll Radiol) 2022; 34: 230-240. [DOI] [PMC free article] [PubMed]

[50] Kamstra J.I., van Leeuwen M., Roodenburg J.L., Dijkstra P.U. Exercise therapy for trismus secondary to head and neck cancer: a systematic review. Head Neck. 2017;39:2352–2362. doi: 10.1002/hed.24859.

[51] Jham B.C., Reis P.M., Miranda E.L., Lopes R.C., Carvalho A.L., Scheper M.A., Freire A.R. Oral health status of 207 head and neck cancer patients before, during and after radiotherapy. Clin. Oral Invest. 2008;12:19–24. doi: 10.1007/s00784-007-0149-5.

[52] Delanian S., Lefaix J.-L. The radiation-induced fibroatrophic process: therapeutic perspective via the antioxidant pathway. Radiother. Oncol. 2004;73:119–131. doi: 10.1016/j.radonc.2004.08.021.

[53] Kamstra J.I., Roodenburg J.L., Beurskens C.H., Reintsema H., Dijkstra P.U. TheraBite exercises to treat trismus secondary to head and neck cancer. Support. Care Cancer. 2013;21:951–957. doi: 10.1007/s00520-012-1610-9.

[54] Deshpande T.S., Blanchard P., Wang L., Foote R.L., Zhang X., Frank S.J. Radiation-related alterations of taste function in patients with head and neck cancer: a systematic review. Curr. Treat. Options Oncol. 2018;19:72–87. doi: 10.1007/s11864-018-0580-7.

[55] Gupta B., Bray F., Kumar N., Johnson N.W. Associations between oral hygiene habits, diet, tobacco and alcohol and risk of oral cancer: a case–control study from India. Cancer Epidemiol. 2017;51:7–14. doi: 10.1016/j.canep.2017.09.003.

[56] Delaney G., Jacob S., Featherstone C., Barton M. The role of radiotherapy in cancer treatment. Cancer. 2005;104:1129–1137. doi: 10.1002/cncr.21324.

[57] Jung Y.-S., Park E.-Y., Sohn H.-O. Oral health status and oral health-related quality of life according to presence or absence of mucositis in head and neck cancer patients. J. Cancer Prevention. 2019;24:43–47. doi: 10.15430/JCP.2019.24.1.43.

[58] Hopkins J., Cescon D.W., Tse D., Bradbury P., Xu W., Ma C., Wheatley-Price P., Waldron J., Goldstein D., Meyer F., Bairati I., Liu G. Genetic polymorphisms and head and neck cancer outcomes: a review. Cancer Epidemiol. Prevention Biomarkers. 2008;17:490–499. doi: 10.1158/1055-9965.EPI-07-2714.

[59] Dijkstra P., Huisman P., Roodenburg J. Criteria for trismus in head and neck oncology. Int. J. Oral Maxillofac. Surg. 2006;35:337–342. doi: 10.1016/j.ijom.2005.08.001.

[60] Fernández-Mateos J., Seijas-Tamayo R., Adansa Klain J.C., Pastor Borgoñón M., Pérez-Ruiz E., Mesía R., Del Barco E., Salvador Coloma C., Rueda Dominguez A., Caballero Daroqui J., Fernández Ruiz E. Genetic susceptibility in head and neck squamous cell carcinoma in a Spanish population. Cancers. 2019;11:493–504. doi: 10.3390/cancers11040493.

[61] Hegde M.N., John A. Radiation induced caries: an overview. J. Health Allied Sci. 2018;8:28–33.

[62] Kolokythas A., Rasmussen J., Reardon J., Feng C. Management of osteoradionecrosis of the jaws with pentoxifylline–tocopherol: a systematic review of the literature and meta-analysis. Int. J. Oral Maxillofac. Surg. 2019;48:173–180. doi: 10.1016/j.ijom.2018.

[63] Chang DT, Sandow PR, Morris CG, Hollander R, Scarborough L, Amdur RJ, et al. Do pre-irradiation dental extractions reduce the risk of osteoradionecrosis of the mandible? Head Neck. 2007;29(6):528–36. 10.1002/hed.20538

[64] Ravasco P, Monteiro-Grillo I, Marques Vidal P, Camilo ME. Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck. 2005;27:659–68. 10.1002/hed.20221